NurExone Biologic Announces Preclinical Evidence of Structural Repair in Injured Spinal Cord Tissue following ExoPTEN Treatment

Core Viewpoint - NurExone Biologic Inc. has successfully closed a private placement and announced promising preclinical imaging results for its lead product ExoPTEN, which shows potential for spinal cord repair following injury [1][10][14]. Company Developments - The company closed a non-brokered private placement of 1,258,072 units at C$0.62 per unit, raising gross proceeds of C$780,004.64, intended for working capital [10][11]. - NurExone is preparing for its first-in-human clinical trial of ExoPTEN, pending regulatory approval [4][14]. Product and Research Insights - Preclinical imaging analysis indicates that ExoPTEN-treated animals exhibited more organized spinal cord tissue compared to untreated controls, with 100% of higher-dose group animals regaining motor function [2][3]. - MRI-Diffusion Tensor Imaging (MRI-DTI) results show that treated spinal cords had greater structural integrity, with higher Fractional Anisotropy (FA) values and lower Mean Diffusivity (MD) values near the injury site, suggesting healthier tissue architecture [5][6][8][9]. - The imaging results support the neuroprotective and regeneration-promoting activity of ExoPTEN in spinal cord injury [3][15]. Market Context - Spinal cord injuries present significant healthcare and economic challenges, with current treatments primarily focusing on stabilization rather than tissue repair. ExoPTEN aims to address this unmet need by supporting nerve repair and restoring function [4][14]. - The market for spinal cord injury treatments is substantial, with NurExone's lead product positioned in a multi-billion-dollar market [14].